Cohort study of quality of life (QOL) after 6 months of therapy by diclofenac, nabumetone, meloxicam or celecoxib in patients with rheumatoid arthritis

Wen Shi,Yongming Wang,Shaoli Li,Min Yan,Duan Li,BinYan Chen,Nengneng Cheng
2004-01-01
Abstract:AIM: To evaluate changes of QOL on patients with rheumatoid arthritis after six-month treatment of diclofenac, nabumetone, meloxicam and celecoxib respectively. METHODS: With the combination of retrospective and prospective methods, the cohort study randomly enrolled 461 subjects with newly developed rheumatoid arthritis. The diclofenac group and nabumetone group each had 131 subjects, the meloxicam group had 144 subjects and celecoxib group had 53 subjects. The observation period was six months. SF-36 questionnaire was adopted to analyze changes in QOL-related variables including physical function, role physical, bodily pain, general health, vitality, social function, role emotional and mental health. RESULTS: Except for "social function" and "role physical", where there were no significant differences in all four groups and the celecoxib group respectively, all other variables were improved significantly with the treatment of studied NSAIDs. Changes of considered variables were not statistically different across four groups. Analyzed by item, with six-month NSAID treatment, the diclofenac group made greater improvement than the celecoxib group in general health (Item 2), bodily pain (Item 7) and total SF-36 Questionnaire score. QOL improvement for those ranked as clinical control was significantly greater than the rest. Improvement was not statistically different between the marked improvement group and the improvement group, which both enjoyed greater improvement than the no effect group. CONCLUSION: QOL improvement was discovered to be positively related to the drug's efficacy. SF-36 Questionnaire (Chinese version) is identified to be useful in the evaluation of QOL change. When analyzed by sub-questionnaire, patient's QOL all improved greatly with the treatment of studied four NSAIDs. Improvements were not substantially different across four groups. These were consistent with traditional efficacy evaluation results. Meanwhile, when analyzed by item, results of the study were somewhat different than those of traditional efficacy evaluation. The diclofenac group made greater improvement than the celecoxib group in general health, bodily pain and total SF-36 Questionnaire score.
What problem does this paper attempt to address?